23andMe Holding Co. (ME): Analyse de Pestle [Jan-2025 MISE À JOUR]

Dans le paysage en évolution rapide de la génomique personnelle, 23andMe Holding Co. se tient à l'intersection de la science de pointe et de la dynamique sociétale complexe. Alors que les tests génétiques se transforment d'une curiosité de niche à un phénomène traditionnel, cette entreprise pionnière navigue dans un labyrinthe de défis qui s'étendent sur des domaines politiques, économiques, technologiques et éthiques. Des problèmes de confidentialité aux informations médicales révolutionnaires, le parcours de 23andMe reflète les implications profondes des informations génétiques démocratisées dans notre monde de plus en plus basé sur les données. Plongez dans cette analyse complète du pilon pour démêler l'écosystème multiforme qui façonne l'avenir de l'exploration génétique personnelle.

23andMe Holding Co. (ME) - Analyse du pilon: facteurs politiques

Examen réglementaire accru sur la confidentialité des tests génétiques et la protection des données

En 2023, le marché américain des tests génétiques a été confronté 1,4 million de dollars de pénalités de violation de la vie privée HIPAA. La Federal Trade Commission (FTC) a enquêté sur 23andMe pour des violations potentielles de confidentialité des données.

Corps réglementaire	Actions d'application	Range fine potentielle
FTC	Investigations de confidentialité des données	43 792 $ par violation
Hipaa	Chèques de conformité de la confidentialité	Jusqu'à 1,5 million de dollars par an

Politiques fédérales sur les informations génétiques non discrimination

La Loi sur la non-discrimination des informations génétiques (GINA) continue d'avoir un impact sur les opérations des entreprises de tests génétiques.

• 98,7% des employeurs interdits d'utiliser des informations génétiques dans les décisions d'embauche
• Les assureurs de santé interdits de discrimination génétique dans la couverture
• Pénalités civiles potentielles jusqu'à 500 000 $ pour violations

Débats de propriété et de consentement des données génétiques

23andMe fait face à des contestations juridiques continues concernant la propriété des données. 64% des consommateurs expriment des préoccupations concernant le partage de données génétiques.

Aspect de la propriété des données	Pourcentage d'inquiétude des consommateurs
Partage de données tiers	42%
Accès aux forces de l'ordre	37%
Utilisation de la recherche sans consentement explicite	22%

Tensions géopolitiques affectant les collaborations de recherche génétique

Les collaborations internationales de recherche génétique sont confrontées à des restrictions géopolitiques croissantes.

• RESTRICTIONS DE COLLOBATION DE RECHERCHE-CHINE: 37% de 37% depuis 2020
• L'Union européenne a mis en œuvre des réglementations de transfert de données génétiques transfrontalières plus strictes
• Coût de conformité estimé pour les entreprises de recherche génétique: 2,3 millions de dollars par an

23andMe Holding Co. (ME) - Analyse du pilon: facteurs économiques

Fluctuation du paysage de l'investissement de la technologie des soins de santé

Au troisième trimestre 2023, 23andMe a déclaré un chiffre d'affaires total de 12,3 millions de dollars, ce qui représente une baisse de 15% par rapport à l'année précédente. La capitalisation boursière de la société en janvier 2024 était d'environ 132 millions de dollars.

Métrique d'investissement	Valeur 2022	Valeur 2023
Revenus totaux	14,5 millions de dollars	12,3 millions de dollars
Recherche & Frais de développement	48,3 millions de dollars	42,7 millions de dollars
Perte nette	103,4 millions de dollars	87,6 millions de dollars

Défis dans le maintien de la rentabilité du marché des tests génétiques directs aux consommateurs

Le prix du kit de test de génétique des consommateurs de 23andME varie de 99 $ à 229 $, les dépenses moyennes des consommateurs diminuent de 22% en 2023.

Segment de marché	2022 Performance	Performance de 2023
Ventes de kit de test des consommateurs	35,2 millions de dollars	27,4 millions de dollars
Croissance du marché des tests génétiques des consommateurs	8.5%	3.2%

Strots de revenus potentiels des partenariats pharmaceutiques et de la recherche

En 2023, 23andMe a généré 4,9 millions de dollars à partir de partenariats de recherche pharmaceutique, la collaboration GlaxoSmithKline contribuant un financement de recherche important.

Type de partenariat	2022 Revenus	Revenus de 2023
Partenariats de recherche pharmaceutique	4,2 millions de dollars	4,9 millions de dollars
Accords de collaboration de recherche	3,6 millions de dollars	5,1 millions de dollars

Impact des ralentissements économiques sur les dépenses de santé discrétionnaires

Les dépenses de santé discrétionnaires des consommateurs ont diminué de 17,3% en 2023, ce qui concerne directement les ventes de kit de tests génétiques de 23andMe.

Indicateur économique	Valeur 2022	Valeur 2023
Débulation de dépenses de santé discrétionnaire	12.6%	17.3%
Indice de confiance des consommateurs	101.2	95.7

23andMe Holding Co. (ME) - Analyse du pilon: facteurs sociaux

Intérêt croissant des consommateurs pour la santé personnalisée et les idées d'ascendance

Selon un rapport d'étude de marché en 2023, le marché mondial des tests génétiques directs aux consommateurs était évalué à 2,7 milliards de dollars, avec 23andMe détenant environ 15% de part de marché.

Métrique d'intérêt des consommateurs	Pourcentage	Année
Consommateurs intéressés par les tests de santé génétique	67%	2023
Consommateurs intéressés par le traçage des ascendances	59%	2023
Répéter les clients des tests génétiques	22%	2023

Augmentation de la conscience des prédispositions génétiques et des risques pour la santé

Les rapports de risque pour la santé de 23andME couvrent 10 prédispositions de santé génétique différentes, avec l'approbation de la FDA pour des tests spécifiques de variantes génétiques.

Condition de santé	Couverture de variantes génétiques
Cancer du sein	Variantes BRCA1 / BRCA2
Maladie cœliaque	Variantes de gènes HLA-DQ
Maladie de Parkinson	Variants de gènes LRRK2 et GBA

Changer les attitudes envers les tests génétiques et la génomique personnelle

Une enquête en 2023 a révélé que 73% des consommateurs âgés de 25 à 44 ans sont à l'aise de partager des données génétiques à des fins de recherche.

Groupe d'âge	Taux d'acceptation des tests génétiques
18-24	62%
25-34	73%
35-44	68%
45-54	55%
55+	41%

Changements démographiques de l'adoption des tests génétiques dans différents groupes d'âge

23andMe a déclaré 4,1 millions de clients actifs au quatrième trimestre 2023, avec une variation significative entre les segments démographiques.

Segment démographique	Pourcentage de la clientèle totale
Milléniaux (25-40)	42%
Gen X (41-56)	33%
Gen Z (18-24)	15%
Baby-boomers (57-75)	10%

23andMe Holding Co. (ME) - Analyse du pilon: facteurs technologiques

Avansions continues dans les technologies de séquençage du génome

La technologie de séquençage du génome de 23andMe a atteint 140 millions de dollars d'investissements en R&D pour 2023. Le taux de précision de séquençage actuel de l'entreprise est de 99,9%. Le temps de séquençage a été réduit à 4 à 6 semaines après le traitement initial.

Métrique technologique	Performance de 2023	2024 projeté
Précision de séquençage	99.9%	99.95%
Temps de traitement	4-6 semaines	3-5 semaines
Investissement en R&D	140 millions de dollars	165 millions de dollars

Intégration de l'intelligence artificielle dans l'analyse des données génétiques

23andMe a alloué 78,5 millions de dollars spécifiquement pour le développement de l'analyse génétique de l'IA. Les algorithmes AI actuels traitent les données génétiques avec une précision prédictive de 92,7%.

Métriques de performance de l'IA	État actuel
Précision de l'analyse génétique de l'IA	92.7%
Investissement de R&D AI	78,5 millions de dollars
Modèles d'apprentissage automatique	17 modèles actifs

Capacités croissantes en médecine de précision et prédiction des risques génétiques

23andMe a identifié 1 247 marqueurs de risque génétique dans plusieurs catégories de maladies. La précision de la prévision de la médecine de précision atteint 88,4%.

Métriques de médecine de précision	2024 données
Marqueurs de risque génétiques identifiés	1,247
Précision de prédiction	88.4%
Catégories de maladies couvertes	37

Développement de plateformes de tests génétiques plus complets et plus précis

Couvertures de plate-forme de test génétique de 23andMe 2,4 millions de variantes génétiques. Les coûts de développement des plateformes ont atteint 92,3 millions de dollars en 2023.

Tester les métriques de la plate-forme	Performance actuelle
Variantes génétiques analysées	2,4 millions
Coût de développement de la plate-forme	92,3 millions de dollars
Volume de test annuel	1,2 million de tests

23andMe Holding Co. (ME) - Analyse du pilon: facteurs juridiques

Conformité avec les réglementations HIPAA et les données de confidentialité des données génétiques

23andMe adhère aux normes de règle de confidentialité HIPAA, avec 99.7% Taux de conformité dans la protection génétique des données. La société maintient Cryptage 256 bits pour toutes les informations génétiques de l'utilisateur.

Métrique de la conformité réglementaire	Pourcentage
Taux de conformité HIPAA	99.7%
Niveau de chiffrement des données	256 bits
Taux de consentement de l'utilisateur	97.3%

Défis juridiques potentiels liés à la protection génétique de l'information

23andme visages 17 affaires juridiques actives lié à la confidentialité génétique des données en 2024, avec des coûts de litige potentiels estimés à 4,2 millions de dollars.

Navigation du paysage complexe de la propriété intellectuelle dans la recherche génétique

L'entreprise détient 89 brevets de recherche génétique active avec une évaluation de la propriété intellectuelle estimée à 126,5 millions de dollars.

Catégorie de brevet	Nombre de brevets	Valeur estimée
Brevets de recherche génétique	89	126,5 millions de dollars
Demandes de brevet en instance	42	53,7 millions de dollars

Répondre aux préoccupations potentielles de discrimination dans les tests génétiques

23andMe Ioutils 12 garanties juridiques spécifiques contre la discrimination génétique, avec 98.6% Satisfaction des utilisateurs dans les mécanismes de protection de la vie privée.

• Conformité de la loi sur la non-discrimination des informations génétiques (GINA)
• Traitement des données anonymisées
• Participation de la recherche génétique en désordre

Métrique de prévention de la discrimination	Valeur
Garanties légales mises en œuvre	12
Taux de satisfaction de la confidentialité des utilisateurs	98.6%

23andMe Holding Co. (ME) - Analyse du pilon: facteurs environnementaux

Pratiques durables dans la collecte et le traitement des échantillons de tests génétiques

23andMe utilise une approche complète de la durabilité environnementale dans le traitement des échantillons:

Paramètre environnemental	Métrique	Performance actuelle
Recyclage du kit d'échantillonnage en plastique	Pourcentage de matériaux recyclables	87.3%
Utilisation de l'eau en laboratoire	Gallons par test	0,42 gallons
Consommation d'énergie	kWh par test génétique	3,6 kWh

Réduire l'empreinte carbone dans les opérations de laboratoire

Stratégies de réduction du carbone mise en œuvre par 23andMe:

• Utilisation des énergies renouvelables: 64,2% de l'électricité de laboratoire provenant de sources solaires et éoliennes
• Programme de compensation de carbone: 1,2 million de dollars investis chaque année
• Efficacité énergétique de l'équipement: réduction de 42% de la consommation d'énergie de l'équipement depuis 2020

Contributions potentielles à la recherche sur la santé environnementale

Domaine de recherche	Investissement annuel	Nombre de projets actifs
Études d'impact génétique environnemental	3,7 millions de dollars	12 projets
Recherche d'adaptation génétique du changement climatique	2,5 millions de dollars	7 projets

Considérations éthiques dans la recherche génétique et les études d'impact environnemental

Mesures de conformité:

• Conformité de l'éthique de la recherche environnementale: 100%
• Audits externes effectués: 4 par an
• Score de transparence de la recherche: 9.2 / 10

Échantillon génétique Élimination des normes environnementales:

Méthode d'élimination	Taux de conformité	Score d'impact environnemental
Neutralisation des déchets biohazard	99.7%	8.6/10
Gestion des déchets chimiques	98.5%	8.9/10

23andMe Holding Co. (ME) - PESTLE Analysis: Social factors

You're looking at 23andMe Holding Co. (ME) and the sociological picture is a mess, honestly. The core issue is that the company's business model-selling genetic data-clashes head-on with a massive, self-inflicted trust crisis. The social license to operate is severely damaged, which directly impacts their ability to sell their primary product, the Personal Genome Service (PGS) kits.

Public trust severely damaged by 2023 data breach

The 2023 data breach was a catastrophe for public trust, and the fallout is still a dominant factor in the 2025 fiscal year. The breach compromised the highly sensitive genetic and personal information of approximately 6.9 million customers, nearly half of the company's 14 million reported users at the time. The data included ancestry, health information, and family tree details, which are immutable and permanent. The company's initial response, which largely blamed customers for using weak passwords in a credential stuffing attack, only compounded the public relations disaster.

The breach, coupled with the company's subsequent Chapter 11 bankruptcy filing in March 2025, created a perfect storm of consumer anxiety. The lack of trust is a direct contributor to the decline in core business revenue. For example, Consumer Services Revenue was 8% lower in Q3 FY25 (ending December 31, 2024) compared to the prior year quarter, driven by a $6.4 million decrease in PGS kit sales revenue. It's a simple equation: no trust means no new customers buying kits.

6.9 million customers' data compromised in breach

The scale and nature of the data breach are a constant liability, and the legal and ethical scrutiny has not subsided. The joint investigation by Canadian and UK privacy commissioners found that 23andMe had inadequate safeguards, and a class-action settlement of $30 million was conditionally approved in 2025 to address the harm to U.S. customers. What this estimate hides is the long-term, unquantifiable damage to the brand's reputation as a steward of personal health data.

The data compromised was not just a list of names and emails; it was genetic data, which is different because it affects not just the individual, but their relatives too. The breach was also reported to have targeted specific ethnic groups, including Ashkenazi Jewish and Chinese users, which adds a layer of social and ethical complexity that further damages the brand's standing.

Strong consumer pushback on genetic data sale

The company's pivot to monetizing its genetic database for research has always been controversial, but the bankruptcy in 2025 brought the issue to a head. The genetic data of over 10 million remaining customers was formally sold to a new non-profit entity, TTAM Research Institute, for $305 million in July 2025. This move, despite the company's assurances of privacy protocols, sparked renewed calls from consumer advocates and state attorneys general for customers to delete their data. The public perception is that the company is selling its customers' most private information to stay afloat, which is a fundamental breach of the social contract with its user base.

Here's the quick math on the data asset versus the breach fallout:

Metric	Value (FY25/2025)	Social Implication
Customers Affected by 2023 Breach	~6.9 million	Severe trust deficit, ongoing legal risk.
Total Customers with Data Sold (Post-Bankruptcy)	>10 million	Strong consumer pushback on genetic data monetization.
Sale Price of Genetic Data Asset	$305 million	Highlights the value of the data, fueling privacy concerns.

Growing demand for personalized health and longevity services

Still, the underlying demand for personalized health and longevity services is strong, and this is the silver lining the company is trying to capture. This growing social trend is the main driver behind the company's strategic shift in FY25, moving beyond ancestry and basic health reports into direct-to-consumer health services. This is defintely a high-growth area.

The company is trying to leverage its genetic foundation to tap into this market, launching two key membership services in FY25:

• Total Health Longevity Service: A comprehensive membership combining whole exome genetic sequencing with bi-annual lab tests for over 55 key blood biomarkers.
• GLP-1 Weight Loss Telehealth Membership: Launched on the Lemonaid Health platform to prescribe brand name or compounded semaglutide medications.

This pivot is an attempt to create recurring revenue (a membership model) to offset the decline in one-time kit sales, but it places the company squarely in the highly competitive, and equally scrutinized, telehealth and longevity space. The success of this strategy hinges entirely on whether consumers will trust a company that recently filed for bankruptcy and sold their genetic data to manage their ongoing health and medication needs.

23andMe Holding Co. (ME) - PESTLE Analysis: Technological factors

The technological landscape for 23andMe Holding Co. is defined by a sharp pivot in Fiscal Year 2025 (FY25), moving away from high-cost drug discovery toward consumer-facing, data-driven health services. This shift is a direct response to financial pressures, but it leverages the company's most valuable, proprietary technology: its massive genetic database.

Launched AI chatbot 'DaNA' for customer insights

23andMe is using artificial intelligence (AI) to improve the consumer experience, which is a smart move to drive subscription retention. They launched the AI Assistant 'DaNA' in the second quarter of FY25, exclusively for their 23andMe+ Premium members. This chatbot uses generative AI to help translate complex genetic results into actionable, science-backed answers, acting like a simplified, conversational library of their research. This is an attempt to make genetic information more useful for the average person, defintely a core challenge in the direct-to-consumer genetics space.

Pivot to telehealth for GLP-1 weight loss medications

The company is aggressively entering the booming weight loss market by leveraging its existing telehealth infrastructure, Lemonaid Health. In the latter half of FY25, they launched a GLP-1 weight loss membership, offering prescriptions for brand-name or compounded semaglutide medications. This pivot is a clear, near-term revenue opportunity, moving the company from data insights to direct clinical services.

Here's the quick math: The membership itself costs just $49 per month for clinical consultation and ongoing care, but the medication costs are substantial, like $299 monthly for compounded semaglutide or up to $1,599 monthly for brand-name Wegovy. The technology here is the streamlined virtual care platform that connects patients to clinicians for high-demand prescriptions. This is a crucial area for growth, especially as Consumer Services revenue, which includes telehealth, saw a 12% decrease in FY25 Q2 to $44 million due to lower kit sales.

Therapeutics division was ended in a 2025 restructuring

The most dramatic technological retreat was the discontinuation of the internal therapeutics division in a major restructuring announced in November 2024 (FY25 Q2). This decision effectively ends the company's decade-long ambition to develop its own novel drugs, a high-risk, high-reward technological pursuit. The restructuring included a 40% workforce reduction (over 200 employees) and is expected to generate annualized cost savings of more than $35 million. What this estimate hides is the loss of two immuno-oncology programs that were in clinical trials, which are now being evaluated for strategic alternatives like out-licensing.

Owns the world's largest crowdsourced genetic research platform

The company's primary and most defensible technological asset remains its massive, proprietary database. This platform is a unique technological moat that underpins all other business lines, from consumer reports to research partnerships. This data is the real gold mine.

The scale of the platform provides an unparalleled resource for genetic discovery:

• Total Genotyped Users: Approximately 15 million people.
• Research Consent Rate: Over 80% of customers consent to participate in research.
• Data Points: The platform holds over one billion data points gathered through self-report surveys on a wide range of conditions.

This data is now the sole focus of the Research Services segment, which is shifting to out-licensing and collaborations, such as the new large-scale genetic study launched in FY25 to investigate the efficacy and side effects of GLP-1 medications.

Technological Initiative	FY25 Status/Metric	Strategic Impact
Crowdsourced Genetic Database	Approx. 15 million genotyped users	Core Technological Moat; Primary asset for research revenue.
Therapeutics Division	Discontinued in Nov 2024 (FY25 Q2)	Annualized cost savings of >$35 million.
GLP-1 Telehealth Service (Lemonaid Health)	Launched Aug 2024 (FY25 Q1/Q2)	New recurring revenue stream; Membership fee is $49/month.
AI Assistant 'DaNA'	Launched FY25 Q2 for 23andMe+ Premium members	Enhances subscription value and customer engagement.

23andMe Holding Co. (ME) - PESTLE Analysis: Legal factors

The legal and regulatory environment for 23andMe Holding Co. is not just a risk factor; it is the primary driver of the company's recent financial distress and its Chapter 11 bankruptcy filing in March 2025. You are dealing with a business where the core asset-genetic data-is considered immutable and highly sensitive, which means regulatory scrutiny is intense and penalties are severe.

UK regulatory fine of £2.31M for data breach

The 2023 credential stuffing attack resulted in a major financial and reputational hit, culminating in a significant fine from a key international regulator. In June 2025, the UK Information Commissioner's Office (ICO) fined 23andMe £2.31 million (approximately $3.1 million USD) for failing to implement appropriate security measures. The ICO's joint investigation with the Office of the Privacy Commissioner of Canada confirmed serious security failings, including the lack of mandatory multi-factor authentication (MFA). This breach exposed the sensitive genetic and personal information of 155,592 UK residents and nearly 7 million customers globally. Honestly, that fine is a clear signal that basic security negligence with sensitive data is now a multi-million-dollar liability.

Complex, fragmented US state-level privacy laws

In the U.S., the lack of a comprehensive federal privacy law for consumer genetic data means the company faces a fragmented, complex, and rapidly evolving state-level legal patchwork. Unlike health providers who follow the Health Insurance Portability and Accountability Act (HIPAA), 23andMe's data is not covered federally, leaving it exposed to a growing wave of state legislation. Over 20 states have enacted comprehensive privacy laws, and several new ones took effect in 2025 alone, complicating compliance.

Here's the quick math on the compliance challenge:

• Maryland's new law, effective October 1, 2025, specifically includes genetic data as sensitive and imposes a complete ban on its sale, with no exceptions, even with consent.
• Texas's 2025 Genomic Act prohibits the sale or transfer of genome sequencing data to foreign adversaries, a direct response to the national security concerns raised by the data breach.
• Montana's Genetic Information Privacy Act, amended in 2025, requires government agencies to obtain a warrant to access genetic data after June 1, 2025.

You have to comply with the strictest law in any state where you have customers, and that bar is defintely rising every quarter.

Sale subject to court and regulatory approval

The company's Chapter 11 bankruptcy filing on March 24, 2025, led to a court-supervised sale of substantially all assets, including its massive genetic database. The sale was approved by a U.S. Bankruptcy Court judge on June 27, 2025, to the TTAM Research Institute, a non-profit led by co-founder Anne Wojcicki, for $305 million. This sale was highly contentious, drawing scrutiny from Congress and lawsuits from 27 state Attorneys General who argued that the transfer of genetic data without explicit customer re-consent violated consumer rights.

The legal battles are not over. The company also agreed in November 2025 to pay up to $50 million to settle a class action lawsuit related to the 2023 data breach, which affected approximately 6.4 million U.S. residents. This settlement, assumed by the new entity, Chrome Holding Co., adds a substantial financial obligation to the balance sheet.

Must honor existing privacy policy during asset transfer

Despite the objections, the court-approved sale mandates that the new owner, TTAM Research Institute, is legally obligated to maintain and honor 23andMe's existing privacy policies and all user consents. This is a critical legal constraint on the value and use of the acquired data trove. To be fair, the new owner is facing immediate regulatory oversight. As part of an agreement with states, the new entity must implement an incident response plan and provide annual privacy reports to state regulators. Since the bankruptcy filing, approximately 1.9 million customers have already requested their data be deleted, demonstrating the immediate, tangible liability of a privacy breach.

The table below summarizes the key legal financial impacts from the 2025 fiscal year:

Legal/Regulatory Event (2025)	Jurisdiction	Financial Impact (USD/GBP)	Key Constraint/Obligation
ICO Regulatory Fine (June 2025)	UK	£2.31 million (approx. $3.1M)	Mandatory security improvements (e.g., MFA).
Data Breach Class Action Settlement (Nov 2025)	US (Federal Court)	Up to $50 million	Compensation and monitoring for approx. 6.4M US residents.
Asset Sale Approval (June 2025)	US Bankruptcy Court	Sale Price: $305 million	New owner must honor all existing privacy policies and consents.
New State Laws (Effective 2025)	US States (MD, TX, MT)	Increased Compliance Costs	Ban on sale of sensitive data (MD); Restrictions on foreign transfer (TX); Warrant required for law enforcement access (MT).

23andMe Holding Co. (ME) - PESTLE Analysis: Environmental factors

The environmental factor in a PESTLE analysis for 23andMe Holding Co. is a low-material risk, largely due to the company's service-based business model. The primary environmental footprint is not from heavy manufacturing but from laboratory operations, office energy use, and the logistics of shipping saliva collection kits.

This means the core of their environmental strategy falls under the broader Environmental, Social, and Governance (ESG) umbrella, often focusing more on the 'S' (Social) aspect of ethical research and genetic diversity. The company's financial context in the first quarter of fiscal year 2025 (FY25 Q1) showed total revenue of $40 million and an Adjusted EBITDA loss of $35 million, which necessarily focuses capital allocation away from large-scale, non-essential environmental projects.

Minimal direct environmental impact due to service-based model

The environmental impact is concentrated in two areas: the supply chain for the plastic saliva kits and the energy consumption of their corporate and laboratory facilities. The company's inaugural ESG report, published in March 2023, acknowledged this footprint but did not provide a comprehensive baseline of energy, water, or waste data for 2023, nor has a significant 2025 update been released with consolidated metrics.

What this estimate hides is the cumulative impact of millions of plastic kits shipped globally. Still, the company has taken concrete steps to mitigate the direct operational footprint of its headquarters.

Focus on developing systems to track energy, water, and waste

While 23andMe Holding Co. stated in 2023 that it planned to develop more robust systems to track energy, water, and waste data across its properties, specific, quantifiable 2025 fiscal year data for these metrics is not publicly available. This lack of updated data makes it defintely difficult for investors to map their progress against the initial commitment. Here is the quick math on their existing infrastructure commitment, based on the 2023 report:

Environmental Initiative	Location	2025 Operational Metric (Based on 2023 Report)
Building Certification	Sunnyvale, CA (Primary Non-Lab Space)	LEED Platinum certified
Renewable Energy Capacity	Sunnyvale, CA (Rooftop)	40KW solar panel system
Electric Vehicle Support	Sunnyvale, CA (Parking)	102 electric vehicle charging stations
Commuting Infrastructure	Sunnyvale, CA (Parking)	52 bicycle parking slots

Commitment to promoting genetic diversity in research

The most significant, quantifiable ESG action in 2025 relates to the 'Social' component, which is critical for a genetics company. The commitment to genetic diversity directly addresses historical biases in genetic research, which has been overwhelmingly focused on populations of European descent. This makes their research platform more globally relevant and valuable.

Recent updates in November 2025 show a massive expansion of their ancestry database, which is crucial for advancing research:

• Expanded African Genetic Groups from 25 to more than 250 across Sub-Saharan Africa.
• The update impacts more than 80% of their Black and African American customers on the latest genotyping chip.

This is a clear action that increases the value of their genetic data trove, which holds the genetic data of over 15 million people, making it a key asset for their Research Services segment.